192 related articles for article (PubMed ID: 25888709)
1. Kinetics differences between PSA bounce and biochemical failure in patients treated with 125I prostate brachytherapy.
Kanzaki H; Kataoka M; Nishikawa A; Uwatsu K; Nagasaki K; Nishijima N; Hashine K
Jpn J Clin Oncol; 2015 Jul; 45(7):688-94. PubMed ID: 25888709
[TBL] [Abstract][Full Text] [Related]
2. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
3. PSA bounce after ¹²⁵I-brachytherapy for prostate cancer as a favorable prognosticator.
Engeler DS; Schwab C; Thöni AF; Hochreiter W; Prikler L; Suter S; Stucki P; Schiefer J; Plasswilm L; Schmid HP; Putora PM
Strahlenther Onkol; 2015 Oct; 191(10):787-91. PubMed ID: 26100965
[TBL] [Abstract][Full Text] [Related]
4. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence.
Mazeron R; Bajard A; Montbarbon X; Gassa F; Malet C; Rocher F; Clippe S; Bringeon G; Desmettre O; Pommier P
Radiat Oncol; 2012 Mar; 7():46. PubMed ID: 22449081
[TBL] [Abstract][Full Text] [Related]
5. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy.
Crook J; Gillan C; Yeung I; Austen L; McLean M; Lockwood G
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):426-33. PubMed ID: 17869662
[TBL] [Abstract][Full Text] [Related]
6. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant.
Patel C; Elshaikh MA; Angermeier K; Ulchaker J; Klein EA; Chehade N; Wilkinson DA; Reddy CA; Ciezki JP
Urology; 2004 Jan; 63(1):110-3. PubMed ID: 14751360
[TBL] [Abstract][Full Text] [Related]
7. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of prostate-specific antigen bounce after 125I brachytherapy for prostate cancer.
Kubo K; Wadasaki K; Kimura T; Murakami Y; Kajiwara M; Teishima J; Matsubara A; Nagata Y
J Radiat Res; 2018 Sep; 59(5):649-655. PubMed ID: 30085076
[TBL] [Abstract][Full Text] [Related]
9. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival.
Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Radiat Oncol; 2017 Jun; 12(1):98. PubMed ID: 28615058
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.
Stock RG; Stone NN; Cesaretti JA
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):448-53. PubMed ID: 12738319
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen bounce is related to overall survival in prostate brachytherapy.
Hinnen KA; Monninkhof EM; Battermann JJ; van Roermund JG; Frank SJ; van Vulpen M
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):883-8. PubMed ID: 21300477
[TBL] [Abstract][Full Text] [Related]
12. [PSA bounce phenomenon after transperineal interstitial permanent prostate brachytherapy for localized prostate cancer].
Morita M; Lederer JL; Fukagai T; Shimada M; Yoshida H
Nihon Hinyokika Gakkai Zasshi; 2004 Mar; 95(3):609-15. PubMed ID: 15103924
[TBL] [Abstract][Full Text] [Related]
13.
Kindts I; Stellamans K; Billiet I; Pottel H; Lambrecht A
Strahlenther Onkol; 2017 Sep; 193(9):707-713. PubMed ID: 28488030
[TBL] [Abstract][Full Text] [Related]
14. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].
Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone.
Nakai Y; Tanaka N; Asakawa I; Anai S; Miyake M; Morizawa Y; Hori S; Owari T; Fujii T; Yamaki K; Hasegawa M; Fujimoto K
Jpn J Clin Oncol; 2020 Jan; 50(1):58-65. PubMed ID: 31665354
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S
BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen bounce in patients treated before 60 years old by iodine 125 brachytherapy for prostate cancer is frequent and not a prognostic factor.
Charret J; Baumann AS; Eschwege P; Moreau JL; Bernier V; Falk AT; Salleron J; Peiffert D
Brachytherapy; 2018; 17(6):888-894. PubMed ID: 30172752
[TBL] [Abstract][Full Text] [Related]
18. Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy.
Matsushima M; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Ohashi T; Mikami S; Miyajima A; Shigematsu N; Oya M
Int J Urol; 2016 Mar; 23(3):247-52. PubMed ID: 26663514
[TBL] [Abstract][Full Text] [Related]
19. Relationship between sexual function and prostate-specific antigen bounce after iodine-125 permanent implant brachytherapy for localized prostate cancer.
Nishihara K; Nakiri M; Chikui K; Suekane S; Matsuoka K; Hattori C; Ogo E; Abe T; Matsumoto Y; Ishitake T
Int J Urol; 2014 Jul; 21(7):658-63. PubMed ID: 24650159
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma.
Guarneri A; Botticella A; Ragona R; Filippi AR; Munoz F; Casetta G; Gontero P; Tizzani A; Ricardi U
World J Urol; 2013 Apr; 31(2):411-5. PubMed ID: 22922810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
